CPD 923 Uses, Dosage, Side Effects and more

CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

Trade Name CPD 923
Generic CPD 923
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in metabolic disease.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share